Jubilant Pharmova Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Jubilant Pharmova Ltd filed with BSE on 27 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jubilant Pharmova reported Q4 FY2026 revenue growth of 19% year-on-year to Rs.2,290 crore, driven by radiopharma, allergy immunotherapy, CDMO sterile injectables and generics, while EBITDA margin declined due to a SPECT products shortage and under-absorption of costs at CMO Montreal. For the full year, revenue grew 14% to Rs.8,280 crore and EBITDA grew 8% to Rs.1,326 crore, with margin down 99 basis points to 15.9%. Management described FY2027 EBITDA margin as a story of two halves, with improvement expected from H2 as Montreal production stabilizes.
Numbers mentioned
Revenue: Rs.2,290 Crores (Q4 FY2026)
p. 3
“In Q4 FY2026, revenue grew by 19% on year-on-year basis to Rs.2,290 Crores on the back of growth in radiopharma and allergy immunotherapy, CDMO sterile injectable and generics.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
EBITDA: Rs.363 Crores (Q4 FY2026)
p. 3
“EBITDA increased 2% on year-on-year basis to Rs.363 Crores.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
EBITDA margin: 15.7% (Q4 FY2026)
p. 3
“EBITDA margin decreased year-on-year by 272 basis points to 15.7% due to shortage in supply of SPECT products in Radiopharmaceuticals and under absorption of costs in CMO Montreal.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Normalized PAT: Rs.129 Crores (Q4 FY2026)
p. 3
“Normalized PAT stood at Rs.129 Crores.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Revenue: Rs.8,280 Crores (FY2026)
p. 3
“Overall, for the full year FY2026, revenue grew by 14% to Rs.8,280 Crores on the back of growth across all business units, particularly CDMO Sterile Injectables.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
EBITDA: Rs.1,326 Crores (FY2026)
p. 3
“EBITDA for the year grew by 8% to Rs.1,326 Crores due to improved performance across all segments except Radiopharmaceuticals.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
EBITDA margin: 15.9% (FY2026)
p. 3
“The EBITDA margins decreased year-on-year by 99 basis points to 15.9% due to lower production at CMO Montreal, particularly in the second half.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Normalized PAT: Rs.442 Crores (FY2026)
p. 3
“Normalized PAT for the year grew by 7% to Rs.442 Crores due to improved operating performance of the business.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Discovery business revenue: north of Rs.650 Crores (FY2026)
p. 6
“So if you look at our FY2026 numbers, our discovery business grew 15% to now north of Rs.650 Crores and the margin also grew proportionately.”
Tushar Gupta, page 6 of the filed PDF · View the filing
Generics business revenue growth: 13% (FY2026)
p. 6
“So, if you look at our generics business, the revenue grew by 13% this year and margin grew by 250%.”
Tushar Gupta, page 6 of the filed PDF · View the filing
Capex: Rs.1,668 Crores (FY2026)
p. 9
“FY2026, we have done a capex of Rs.1,668 Crores.”
Arun Kumar Sharma, page 9 of the filed PDF · View the filing
Net debt: Rs. 1,952 crore (as of Q4 FY2026)
p. 13
“Yes so net debt is Rs. 1,952 crore and like I said in the earlier answer also, we see this net debt going down from FY2028 onwards when we have Line 3 and Line 4 growing in revenue and EBITDA there.”
Arun Kumar Sharma, page 13 of the filed PDF · View the filing
Tax rate: around 33%
p. 13
“Second question on the tax rate see, our tax rate is around 33%.”
Arun Kumar Sharma, page 13 of the filed PDF · View the filing
Allergy business US share: about 90%
p. 11
“Thank you for the question, this is Anuj, so split of US and non-US about 90% is US and then about 8% to 10% is non-US.”
Anuj Mohnot, page 11 of the filed PDF · View the filing
US allergy market growth: 3% to 4%, 5%
p. 12
“So Shrikant this is Priyavrat, the allergy business in the US is growing at about 3% to 4%, 5% maybe.”
Priyavrat Bhartia, page 12 of the filed PDF · View the filing
H1 FY2027 SPECT revenue impact: $14 million (H1 FY2027)
p. 8
“Just to give you a sense, the revenue impact in H1 is about $14 million on SPECT.”
Harsher Singh, page 8 of the filed PDF · View the filing
Montreal EBITDA loss: about Rs.200 Crores (FY2026)
p. 7
“Vinay, as we look at Montreal, last year, including exceptional items, it was about Rs.200 Crores loss.”
Harsher Singh, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — H2 FY2027
stated conditionally by Arun Kumar Sharma
p. 3
“As production at CMO Montreal stabilizes, we expect EBITDA margin to start strengthening from H2 FY2027 onwards.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Line 3 peak revenue — 80 million to 90 million · one-and-a-half to two years earlier than projected
stated firmly by Chris Preti
p. 4
“we expect to reach peak revenue in line 3 in one-and-a-half to two years earlier as projected and achieve an 80 million to 90 million specifically for line 3”
Chris Preti, page 4 of the filed PDF · View the filing
Line 3 commercial production start — late FY2027
stated conditionally by Chris Preti
p. 4
“Specifically, commercial production, as to your question, will commence in late FY2027, subject to FDA approval of these products.”
Chris Preti, page 4 of the filed PDF · View the filing
Radiopharma consolidated growth — low double digits · FY2027
stated firmly by Harsher Singh
p. 5
“Look, we expect that the business will grow in the sort of low double digits and we expect margins to remain in the 38% to 40% range.”
Harsher Singh, page 5 of the filed PDF · View the filing
API EBITDA margin — short to medium term
stated as an aspiration by Tushar Gupta
p. 6
“But in short to medium term, you should expect that to go up driven by custom manufacturing revenue.”
Tushar Gupta, page 6 of the filed PDF · View the filing
Generics EBITDA margin — close to 15%
stated as an aspiration by Tushar Gupta
p. 6
“So, you should expect the margin to be close to 15%, the revenues to be in line with what we committed for 2030 as part of our vision.”
Tushar Gupta, page 6 of the filed PDF · View the filing
Net debt — zero · FY2030
stated firmly by Arun Kumar Sharma
p. 9
“And as regards to net debt, we are committed to achieve net debt zero by 2030.”
Arun Kumar Sharma, page 9 of the filed PDF · View the filing
Net debt reduction start — FY2028
stated firmly by Arun Kumar Sharma
p. 9
“And you can see this reduction in net debt from FY2028 onwards.”
Arun Kumar Sharma, page 9 of the filed PDF · View the filing
Line 3 tech transfer revenue — $60 million to $80 million · FY2027
stated firmly by Chris Preti
p. 10
“So the answer is yes, we expect to generate approximately $60 million to $80 million in revenue from Line 3 as we move into FY2027, predominantly coming from the tech transfers of the products that I mentioned.”
Chris Preti, page 10 of the filed PDF · View the filing
MIBG NDA filing — H2 FY2027
stated firmly by Harsher Singh
p. 8
“Right now, we continue to expect that we will file MIBG's NDA in the second half of FY2027.”
Harsher Singh, page 8 of the filed PDF · View the filing
Montreal loss trajectory — FY2027
stated firmly by Harsher Singh
p. 7
“Based on the run-rate for that business, we expect that the next financial year will look similar to the last financial year.”
Harsher Singh, page 7 of the filed PDF · View the filing
Montreal loss reduction — FY2028
stated firmly by Harsher Singh
p. 8
“So 2028, you should see a meaningful reduction in losses.”
Harsher Singh, page 8 of the filed PDF · View the filing
Line 5 revenue start — FY2029
stated firmly by Harsher Singh
p. 8
“We are going to start to see revenue from line 5 come in FY2029, as we start the media fills there.”
Harsher Singh, page 8 of the filed PDF · View the filing
MIBG accelerated review — six-month review
stated conditionally by Harsher Singh
p. 10
“First, on approval timelines, an accelerated review suggests a six-month review should there be no gaps in our filing.”
Harsher Singh, page 10 of the filed PDF · View the filing
PET pharmacies commercialization — first three · next year
stated conditionally by Harsher Singh
p. 12
“Our PET pharmacies, which we are standing up, the first of them should be commercialized next year, the first three of them.”
Harsher Singh, page 12 of the filed PDF · View the filing
H2 FY2027 EBITDA margin — 17% to 18% · H2 FY2027
stated conditionally by Arun Kumar Sharma
p. 14
“Yes, see, I am not supposed to say the exact margins, but as you are asking it again and again, so I can see, H2 margins would be in the range of 17% to 18%.”
Arun Kumar Sharma, page 14 of the filed PDF · View the filing
Capex — similar to FY2026 · FY2027
stated firmly by Arun Kumar Sharma
p. 9
“In FY2027, we are looking at a similar capex to FY2026.”
Arun Kumar Sharma, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Chris Preti said over 10 products are undergoing tech transfer, with commercial production starting late FY2027 subject to FDA approval, and about 80% are complex biologics commanding a price premium.
Answered by Chris Preti
Asked by Shrikant Akolkar: What is the update on Line 3 and the 10+ molecule pipeline, and when will commercials start?
p. 4
“Specifically for line 3, we have approximately 10 plus products, as you mentioned, across multiple formats and vial sizes undergoing tech transfer as we speak.”
Chris Preti, page 4 of the filed PDF · View the filing
Harsher Singh explained that SPECT cold kit availability from CMO Montreal drives the difference, with product release expected mid to end Q2 lifting Q3 and Q4.
Answered by Harsher Singh
Asked by Shrikant Akolkar: What cost pressure is expected in radiopharma in H1 FY2027 and what changes in H2?
p. 5
“We are manufacturing product now at that site and we expect it to release mid to end Q2.”
Harsher Singh, page 5 of the filed PDF · View the filing
Tushar Gupta said progress is being made onboarding customers on custom manufacturing revenue, which is expected to drive future utilization and profitability.
Answered by Tushar Gupta
Asked by Vishal Manchanda: Is there progress on tying up with innovators on the API/custom manufacturing front?
p. 5
“We have been trying to get customers onboarded on the custom manufacturing revenue, as you mentioned so we are making progress and we expect the custom manufacturing revenue mix to drive the utilization and profitability going forward.”
Tushar Gupta, page 5 of the filed PDF · View the filing
Priyavrat Bhartia said investments are evaluated against a ROCE threshold and no major capex is foreseen beyond current committed projects for the next 12-18 months.
Answered by Priyavrat Bhartia
Asked by Gaurav (Bandhan AMC): How is capital allocation decided across the multiple business segments?
p. 7
“In terms of capital allocation, we have a ROCE threshold that we look at.”
Priyavrat Bhartia, page 7 of the filed PDF · View the filing
Harsher Singh said FY2027 losses would look similar to FY2026, with a meaningful reduction expected in FY2028 and Line 5 revenue starting in FY2029.
Answered by Harsher Singh
Asked by Vinay Jain: What is the path to turning around the Montreal plant and reducing losses?
p. 7
“We expect to see a meaningful reduction in that P&L through cost cutting that will take place this year, which will be impacting next year in 2028.”
Harsher Singh, page 7 of the filed PDF · View the filing
Arun Kumar Sharma detailed remaining capex on Spokane Line 4, Montreal Line 5 and PET pharmacies, and reaffirmed the commitment to reach net debt zero by FY2030.
Answered by Arun Kumar Sharma
Asked by Aditya Chheda: Can management quantify capex for FY2027/FY2028 and comment on deleveraging?
p. 9
“And as regards to net debt, we are committed to achieve net debt zero by 2030.”
Arun Kumar Sharma, page 9 of the filed PDF · View the filing
Harsher Singh said a prior discontinued I-131 MIBG product (Azedra) complicates eligibility for the voucher.
Answered by Harsher Singh
Asked by Shrikant Akolkar: Will MIBG be eligible for a priority review voucher?
p. 10
“However, its previous approval does muddy the water on our ability to get a priority review voucher.”
Harsher Singh, page 10 of the filed PDF · View the filing
Harsher Singh said the company expects to launch MIBG itself given its downstream and commercial capabilities.
Answered by Harsher Singh
Asked by Shrikant Akolkar: Will Jubilant launch MIBG itself or license it out?
p. 10
“In terms of your second question, we expect to launch this product ourselves.”
Harsher Singh, page 10 of the filed PDF · View the filing
Priyavrat Bhartia said growth drivers include gaining US market share and expanding into non-US markets, especially Europe.
Answered by Priyavrat Bhartia
Asked by Shrikant Akolkar: What is driving the allergy business's US and non-US growth?
p. 12
“The drivers for growth are obviously higher share that we are gaining of expanding into non-US markets.”
Priyavrat Bhartia, page 12 of the filed PDF · View the filing
Arun Kumar Sharma stated net debt at Rs.1,952 crore and said the tax rate, currently around 33%, should gradually decline as margins improve.
Answered by Arun Kumar Sharma
Asked by Vishal Manchanda: What is the current net debt and expected tax rate trend?
p. 13
“Yes so net debt is Rs. 1,952 crore and like I said in the earlier answer also, we see this net debt going down from FY2028 onwards when we have Line 3 and Line 4 growing in revenue and EBITDA there.”
Arun Kumar Sharma, page 13 of the filed PDF · View the filing
Arun Kumar Sharma indicated H2 margins would be in the 17-18% range.
Answered by Arun Kumar Sharma
Asked by Shrikant Akolkar: Can management quantify the H1 vs H2 FY2027 margin difference?
p. 14
“So that should give you an idea that how will our FY2028 spell out going forward from there on.”
Arun Kumar Sharma, page 14 of the filed PDF · View the filing
Risks flagged
Shortage in supply of SPECT products affecting Radiopharmaceuticals margins
p. 3
“EBITDA margin decreased year-on-year by 272 basis points to 15.7% due to shortage in supply of SPECT products in Radiopharmaceuticals and under absorption of costs in CMO Montreal.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Lower production at CMO Montreal, particularly in the second half
p. 3
“The EBITDA margins decreased year-on-year by 99 basis points to 15.9% due to lower production at CMO Montreal, particularly in the second half.”
Arun Kumar Sharma, page 3 of the filed PDF · View the filing
Revenue impact from SPECT product shortage in H1 FY2027
p. 8
“Just to give you a sense, the revenue impact in H1 is about $14 million on SPECT.”
Harsher Singh, page 8 of the filed PDF · View the filing
Delay in one FY2027 pipeline product launch pushed to FY2028
p. 8
“When we talk about the rest of the pipeline, while one product in FY2027 got pulled out, I think what we have to recognize is we have taken the entire pipeline out of CMO Montreal and put it in a third party CMO network.”
Harsher Singh, page 8 of the filed PDF · View the filing
Competitive intensity in large pharma customer segment for discovery business
p. 6
“I think in the short term, we expect some competitive intensity in the large pharma customer segment, right.”
Tushar Gupta, page 6 of the filed PDF · View the filing
Prior discontinued MIBG-related product complicating priority review voucher eligibility
p. 10
“However, its previous approval does muddy the water on our ability to get a priority review voucher.”
Harsher Singh, page 10 of the filed PDF · View the filing
FDA approval timing dependency for PET pharmacy commercialization
p. 12
“We will see a couple that may go over into the next year, but we are just working through qualification timelines, and we are a little dependent on when the FDA comes in to be able to approve the sites.”
Harsher Singh, page 12 of the filed PDF · View the filing
Unshielded expenses keeping tax rate elevated
p. 13
“We have some unshielded expenses due to which tax rate is higher than 33%.”
Arun Kumar Sharma, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.